Bank of America
LCTX icon

Bank of America’s Lineage Cell Therapeutics LCTX Stock Holding History

Bank of America’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,859
Closed -$6K – 7335
2014
Q4 		$6K Buy
+1,859
New +$5.03K ﹤0.01% 7219

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's LCTX Position: Q1 2026 in Review

Bank of America increased its Lineage Cell Therapeutics (LCTX) stake by 112% in Q1 2026, buying an estimated $374K and bringing the position to 419,355 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #4741.

Bank of America first reported a position in LCTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.17M in Q1 2023. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Bank of America held 419,355 shares of Lineage Cell Therapeutics worth $663K as of Q1 2026.
  • Bank of America bought 221,506 Lineage Cell Therapeutics shares in Q1 2026, an estimated $374K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4741 holding.
  • Bank of America first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Lineage Cell Therapeutics position peaked at $2.17M in Q1 2023.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.